BAYN.DE - Bayer Aktiengesellschaft

XETRA - XETRA Delayed Price. Currency in EUR
+0.33 (+0.49%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close66.90
Bid67.30 x 28400
Ask67.32 x 2100
Day's Range67.05 - 67.75
52 Week Range52.02 - 79.95
Avg. Volume3,291,965
Market Cap62.695B
Beta (3Y Monthly)1.10
PE Ratio (TTM)111.31
EPS (TTM)0.60
Earnings DateOct 30, 2019
Forward Dividend & Yield2.80 (4.19%)
Ex-Dividend Date2019-04-29
1y Target Est120.99
  • Startup uses remittances to remove 'time and distance' from health care
    Yahoo Finance

    Startup uses remittances to remove 'time and distance' from health care

    Hoy Health launched less than two years ago, but sees strong growth potential in paving the way to the Latin American health care market.

  • Bayer to reduce size of management board to five

    Bayer to reduce size of management board to five

    Bayer management board members Hartmut Klusik and Kemal Malik will leave at the end of the year without a replacement, as the German drugmaker reduces its board to five seats to cut costs. "By streamlining the structure of the Board of Management, we are optimizing the allocation of responsibilities and contributing to the company's ongoing efficiency program," Werner Wenning, chairman of the non-executive supervisory board, said in a statement on Tuesday. Bayer said last year it would lean more strongly on external firms and institutions for a better drug development pipeline, which most analysts regard as too thin to make up for an expected decline in revenues from its two pharma bestsellers from about 2024.

  • Reuters

    Big Ag wants a cut of booming fake-meat market

    WINNIPEG, Manitoba/CHICAGO Sept 9 (Reuters) - Bunge Ltd, one the world's biggest grain traders, recently disclosed the 1.6% stake it had purchased in the fast-growing fake-meat startup Beyond Meat. The play looked smart after the stock surged more than 250% since the faux burger and sausage maker's initial public offering in May. Indeed, Beyond Meat's market capitalization of $9.9 billion is now larger than Bunge's , a 201-year-old firm with 31,000 employees. No wonder many top agricultural firms want to grab their cut of the booming market for plant-based fake meat.

  • Reuters

    INSIGHT-Inside drugmakers' strategy to boost cancer medicines with "Lazarus effect"

    In the halls of MD Anderson Cancer Center, the drug Vitrakvi is known for having a "Lazarus effect" in some patients because it can reverse late-stage cancer that has defied all other treatment options. Developed by Eli Lilly and Co's Loxo Oncology and marketed by German drugmaker Bayer, it fights a rare genetic mutation that appears in less than 1% of solid tumors, regardless of where they appear in the body. Finding those patients will require widespread adoption of sophisticated tests that look for multiple genetic alterations that could be driving the cancer.

  • Bayer says Monsanto's list of influential people was not illegal

    Bayer says Monsanto's list of influential people was not illegal

    Bayer said a law firm it commissioned to investigate lists compiled by Monsanto of European journalists, politicians and researchers had found no evidence of illegal behaviour. French prosecutors in May opened an inquiry after newspaper Le Monde filed a complaint alleging Monsanto, which was bought by Bayer for $63 billion, had kept files of influential people in a bid to sway public opinion on its pesticides. "There is no question that the ... stakeholder lists created were detailed, methodical, and designed to strongly advocate Monsanto's positions to stakeholders and to the public," Bayer quoted the report by law firm Sidley Austin as saying.

  • Reuters

    UPDATE 2-Brazil judge orders Bayer to deposit $69 mln in soy patent dispute

    A Brazilian judge has ordered Germany's Bayer to deposit an additional 286 million reais ($69.4 million) in an escrow account due to a patent dispute with local soybean farmers, according to a court decision seen by Reuters. Federal Judge Vanessa Gasques in the state of Mato Grosso issued the ruling late on Tuesday, ordering the company to make the deposit within 48 hours. Bayer previously deposited 11.9 million reais related to the case, corresponding to 4% of the royalties in question from the genetically modified Intacta soybean seed.

  • Germany Aims to Ban Glyphosate Usage in Weedkillers

    Germany Aims to Ban Glyphosate Usage in Weedkillers

    (Bloomberg) -- Angela Merkel’s government aims to phase out herbicides containing glyphosate by the end of 2023, a move that could generate further headwinds for German drug and chemical giant Bayer AG.As part of the proposal approved by her cabinet on Wednesday, the government intends to oppose any request for the EU to renew the license to produce the weedkiller, according to a release by the environment ministry. Jurisdiction over licensing lies with Brussels and not with EU member countries."I don’t expect that there will be a majority anywhere in the EU for glyphosate after 2022," Environment Minister Svenja Schulze said at a news conference in Berlin.The move could prove a further setback for Bayer, which faces massive U.S. lawsuits alleging its Roundup herbicide causes cancer.“We disagree with the German government’s decision to ban glyphosate by the end of 2023," Liam Condon, head of Bayer’s Crop Science Division, said in a statement. "The ruling ignores decades of scientific judgment from independent regulatory agencies around the world that glyphosate is safe when used properly."The chemical industry association VCI, said the government was getting ahead of itself by banning a product before a decision had been made by the relevant European Union authority. EU law does not allow for unilateral decisions by member states, it said.“For the companies in our sector, today’s decision means a massive loss of certainty for planning,” Utz Tillmann, managing director of VCI said in a statement. “Business must be able to count on reliable conditions.”Agriculture Minister Julia Kloeckner stressed that the product continues to be legal under EU law but that farming policies would become "greener" going forward. By 2023 Germany aims to reduce the use of herbicides containing glyphosate by at least 75%.For years glyphosate has been a hot button topic in Germany, with a raging public debate over its potential impact on biodiversity and health. Last month German state-owned rail carrier Deutsche Bahn said it plans to cut glyphosate usage in half by 2020.The German government’s policy statement, which is not legally binding, follows nation-wide protests and demands from her junior coalition partner, the Social Democrats, for more decisive action on environmental issues. The renewed focus on climate has helped boost the Green Party in opinion polls, to the detriment of the mainstream parties.Two years ago the weedkiller dispute caused a storm inside Merkel’s cabinet when her agriculture minister unilaterally voted in favor of extending the use of glyphosate.(Updates with details, comments, reactions throughout.)\--With assistance from Iain Rogers.To contact the reporter on this story: Birgit Jennen in Berlin at bjennen1@bloomberg.netTo contact the editors responsible for this story: Ben Sills at, ;Chad Thomas at, Raymond Colitt, Andrew BlackmanFor more articles like this, please visit us at©2019 Bloomberg L.P.

  • Bayer hires former J&J executive for more pharma deals

    Bayer hires former J&J executive for more pharma deals

    Bayer said it hired Johnson & Johnson executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit, as the German drugmaker turns to outside sources to boost its development pipeline. De Backer will take the role of Head of Business Development & Licensing at Bayer's pharmaceuticals division, joining from rival J&J, where she lead business development activities across different therapeutic areas and regions. Based in Berkeley, California, the Belgian national will have a more senior role than her predecessor, reporting directly to the head of pharmaceuticals, Stefan Oelrich, and taking a seat on the division's Executive Committee.

  • China Drone Attack on Crop-Eating ‘Monster’ Shows 98% Kill Rate

    China Drone Attack on Crop-Eating ‘Monster’ Shows 98% Kill Rate

    (Bloomberg) -- An army of drones deployed to fight a crop-devouring pest in a southern area of China has recorded a mortality rate of as high as 98%, according to the manufacturer.XAG, a Guangzhou-based drone maker, teamed up with Germany’s Bayer Crop Science in a drone swarm operation to kill the fall armyworm in China’s Guangxi region. The autonomous devices, loaded with low-toxicity insecticide, have also successfully managed the pests in a government-led operation in the southwest province of Yunnan, XAG said.“It is the ‘crop-devouring monster’ that attacks over 80 crop varieties,” XAG said in a statement Monday. Most farmers resort to traditional insecticide sprayers, which not only fail to move fast enough against the “ravenous, fast-moving fall armyworm” that can fly up to 100 kilometers in one night, but also expose them to dangerous chemicals, it said.This Is the Caterpillar That’s Coming for Your Lunch: QuickTakeThe fall army worm, a crop-devouring pest, has spread from the Americas to Africa and Asia, gorging on rice, corn, vegetables, cotton and more. Since arriving in China, it has advanced north, affecting 950,000 hectares of crops in 24 provinces as of mid-August, including parts of Hebei, Shaanxi and Shandong, according to an official report published late last month. Outbreaks at 90% of the affected areas are now under control, the report said.Drones can safely operate after sunset to kill the pests, which feed most actively at night, XAG said. According to a local media report, drones have also effectively helped to control the spread of the pests found in some cornfields in the northern province of Henan.To contact Bloomberg News staff for this story: Niu Shuping in Beijing at nshuping@bloomberg.netTo contact the editors responsible for this story: Anna Kitanaka at, Alexander KwiatkowskiFor more articles like this, please visit us at©2019 Bloomberg L.P.

  • Benzinga

    Bank Of America Downgrades Elanco Animal Health, Says Too Much Uncertainty Around Bayer Deal

    Last week, Elanco Animal Health Incorporated (NYSE: ELAN) announced plans to acquire Bayer’s (OTC: BAYRY) Animal Health business for $7.6 billion. The purchase price of Elanco Animal Health’s deal to acquire Bayer’s Animal Health business is much lower than what some reports had speculated, Ryskin said in the note.

  • Reuters

    UPDATE 3-Companies file suit in Canada challenging new rules to lower drug prices

    Five pharmaceutical companies said on Friday they have filed a complaint in a Canadian court challenging the constitutionality of new Canadian regulations meant to lower patented drug prices, setting up a fight with the federal government ahead of an Oct. 21 election. The complaint was filed in Quebec's Superior Court by the Canadian arms of U.S.-based Merck & Co and Johnson & Johnson's Janssen Inc, Germany's Bayer AG and Boehringer Ingelheim, and France's Servier Inc. The filing ratchets up a confrontation between the pharmaceutical industry and the Liberal government of Prime Minister Justin Trudeau, which has vowed to make affordability a key plank of its election campaign.

  • Reuters

    PRESS DIGEST- Wall Street Journal - Aug 21

    The following are the top stories in the Wall Street Journal. - Bayer AG is selling its animal-health business to American rival Elanco Animal Health Inc for $7.6 billion, part of the German drug-and-chemicals giant's plan to shed assets amid mounting legal liabilities from its Roundup herbicide. - Walmart Inc is suing Tesla Inc alleging that some of the company's solar panels sparked roof fires at several of the retailer's locations, adding to the problems the electric-car maker has had with its venture to power homes and stores.

  • Motley Fool

    What Happened in the Stock Market Today

    Home Depot rose despite reporting mixed results, and Elanco announced a deal with Bayer for its animal health business.

  • Pharma Stock Dives After Unveiling $7.6 Billion Animal-Health Merger
    Investor's Business Daily

    Pharma Stock Dives After Unveiling $7.6 Billion Animal-Health Merger

    Elanco Animal Health stock toppled Tuesday after announcing its $7.6 billion takeover of Bayer's animal health segment. Elanco stock plunged almost 9% at the close of the stock market.

  • Moody's

    Elanco Animal Health Incorporated -- Moody's places Elanco's Baa3 ratings under review for downgrade

    Moody's Investors Service ("Moody's") placed the ratings of Elanco Animal Health Incorporated ("Elanco") under review for downgrade following the announcement of its definitive agreement to acquire Bayer AG's animal health business. Ratings placed under review include the Baa3-rated unsecured notes, unsecured term loans, and revolving credit facility. Elanco expects the transaction to close in mid-2020, pending regulatory review.


    Elanco Stock Tumbles After It Announces a Deal to Acquire Bayer’s Animal-Health Business

    Elanco Animal Health is one of the largest companies in its field and it plans to get a lot bigger with the $7.6 billion acquisition of Bayer’s animal-health business.

  • Bayer to sell its animal health unit to Elanco for $7.6B
    Yahoo Finance Video

    Bayer to sell its animal health unit to Elanco for $7.6B

    Yahoo Finance’s Adam Shapiro, Sibile Marcellus, Anjalee Khemlani, and Rick Newman discuss.